First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Moist wound dressing for chronic wound treatment now available in Germany
Subscribe To Our Newsletter & Stay Updated
